Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KHK | P50053 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.40 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30376853 | 1.00 | ALDH1A1 (0.43) | ALDH1A1KHKNPSR1CYP1A2CYP2C9 | |
| SCHEMBL30072552 | 0.82 | KHK (0.48) | ALDH1A1KHKNPSR1CYP1A2CYP2C9 | |
| SCHEMBL1825631 | 0.82 | KHK (0.48) | ALDH1A1KHKNPSR1CYP1A2CYP2C9 | |
| SCHEMBL2708620 | 0.79 | RPS6KA5 (0.39) | ALDH1A1KHKNPSR1CYP1A2CYP2C9 | |
| SCHEMBL30242159 | 0.77 | ALDH1A1 (0.49) | ALDH1A1KHKNPSR1CYP1A2CYP2C9 | |
| SCHEMBL18121299 | 0.77 | KHK (0.48) | ALDH1A1KHKNPSR1CYP1A2CYP2C9 | |
| SCHEMBL26127739 | 0.77 | ALDH1A1 (0.41) | ALDH1A1KHKNPSR1CYP1A2CYP2C9 | |
| SCHEMBL333768 | 0.77 | ALDH1A1 (0.49) | ALDH1A1KHKNPSR1CYP1A2CYP2C9 | |
| SCHEMBL19837355 | 0.77 | RPS6KA5 (0.41) | ALDH1A1KHKNPSR1CYP1A2CYP2C9 | |
| SCHEMBL566120 | 0.77 | CSNK1A1 (0.52) | ALDH1A1KHKCYP1A2CYP2C19RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 528 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113698342-B | Preparation method of 2, 6-dichloronicotinic acid as key intermediate heterocyclic compound of orbetinib | 南京恒远科技开发有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-113698342-A | Preparation method of 2, 6-dichloronicotinic acid as key intermediate heterocyclic compound of orbetinib | 南京恒远科技开发有限公司 | 2021-11-26 | — | — | CN | claimed |
| CN-111153825-A | Method for preparing amide compound by using supported metal oxide catalytic material | 浙江大学 | 2020-05-15 | — | — | CN | claimed |
| US-20040180922-A1 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | US | claimed |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4743462-A1 | COMPOUNDS COMPRISING A NAPHTHYRIDINE OR PYRIDOPYRIMIDINE CORE AS PTC READ-THROUGH AGENTS | Tay Therapeutics Limited (GB) | 2026-05-20 | — | — | EP | disclosed |
| CN-117062813-B | Polycyclic compound and application thereof | 四川汇宇制药股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12630549-B2 | Pyrazoleamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12583852-B2 | Heterocycle derivative | JW PHARMACEUTICAL CORPORATION (KR) | 2026-03-24 | — | — | US | disclosed |
| EP-4709481-A1 | 5,6-FUSED AND 6,6-FUSED BICYCLIC ALCOHOLS AND ETHERS AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | Amgen Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | SPRINGWORKS THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | CARDURION PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0942911-A1 | BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS | Abbott Laboratories (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5891882-A | TREATING BENIGN PROSTATIC HYPERPLASIA OR OTHER UROLOGICAL DISEASES SUCH AS BLADDER OUTLET OBSTRUCTION AND NEUROGENIC BLADDER, OR GYNECOLOGICAL SYNDROMES SUCH AS DYSMENORRHEA | ABBOTT LABORATORIES (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1998024791-A1 | BENZOPYRANOPYRROLE AND BENZOPYRANOPYRIDINE ALPHA-1 ADRENERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-06-11 | — | — | WO | disclosed |
| EP-0700903-B1 | PROCESS FOR PRODUCING CYANOPYRIDINE | IHARA CHEMICAL IND CO (JP) | 1997-11-12 | — | — | EP | disclosed |
| US-5675012-A | REACTING AMMONIUM HALIDE WITH TRICHLOROMETHYLPYRIDINE IN PRESENCE OF A COPPER AND ZINC COMPOUND | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1997-10-07 | — | — | US | disclosed |
| EP-0700903-A1 | PROCESS FOR PRODUCING CYANOPYRIDINE | IHARA CHEMICAL INDUSTRY CO., LTD. (JP) | 1996-03-13 | — | — | EP | disclosed |
| US-4814456-A | Chlorinating waste streams to recover cyanopyridine contained therein | THE DOW CHEMICAL COMPANY (US) | 1989-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528816-B2 | Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors | RYR2, CACNA1C, CAMK4 | ALDH1A1 1793/4885KHK 1300/4885NPSR1 2261/4885 |
| US-12552772-B2 | 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD | YAP1, TEAD3, TEAD2 | ALDH1A1 1935/4885KHK 3745/4885NPSR1 4484/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | ALDH1A1 632/4885KHK 1338/4885NPSR1 159/4885 |
| US-12583852-B2 | Heterocycle derivative | AR, SRD5A1, NR5A1 | ALDH1A1 1733/4885KHK 3410/4885NPSR1 4051/4885 |
| US-20040180922-A1 | Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses | NFKBIA, IKBKB, CHUK | ALDH1A1 2562/4885KHK 763/4885NPSR1 4553/4885 |
| US-12630549-B2 | Pyrazoleamide derivatives | CYP11B2, CYP11B1, ADRA1B | ALDH1A1 439/4885KHK 1298/4885NPSR1 2423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.